Injectable silk protein as a treatment for osteoarthritis

AFFILIATION:   Cocoon Biotech Inc., Boston, Massachusetts, United States


Track: Medical & Biotech
Area: Advanced Material Platforms
Tech Readiness: TRL 5

Tech Brief: Cocoon's silk protein gel loaded with an anti-pain and anti-inflammatory drug is injected directly into the knee joint where it delivers the drug locally providing superior pain relief without systemic side effects.


Value Proposition: Greater than 90% of warriors presenting with osteoarthritis (OA) attributed the disability to combat injury. Additionally, OA is the main source of disability in military members (Rivera et al., 2012). It has also been reported that the incidence of meniscal injury among the active duty US military was ten fold higher than amongst civilian populations (Jones et al., 2012). As a result of the high rate of joint injuries in the military, the incidence of OA among both active-duty soldiers and military veterans is more than twice the age-adjusted general population incidence. The intra-articular formulation of Cocoon's silk protein gel with an anti-pain and anti-inflammatory medication will have direct relevance to treating the acute/sub-chronic pain, inflammation, and functional deficits that are initiated immediately after an acute joint injury. In addition, the product will also be relevant to treating the chronic pain and inflammation that accompanies the onset of degenerative OA after an acute joint injury in both the military and VA populations.


Org Type: Early-stage Startup (Seed)